ECSP19078196A - Composiciones terapéuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato - Google Patents

Composiciones terapéuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato

Info

Publication number
ECSP19078196A
ECSP19078196A ECSENADI201978196A ECDI201978196A ECSP19078196A EC SP19078196 A ECSP19078196 A EC SP19078196A EC SENADI201978196 A ECSENADI201978196 A EC SENADI201978196A EC DI201978196 A ECDI201978196 A EC DI201978196A EC SP19078196 A ECSP19078196 A EC SP19078196A
Authority
EC
Ecuador
Prior art keywords
disoproxil fumarate
therapeutic compositions
compositions including
tenofovir disoproxil
rilpivirine hcl
Prior art date
Application number
ECSENADI201978196A
Other languages
English (en)
Inventor
Mark Menning
Reza Oliyai
Lauren Wiser
Original Assignee
Janssen Sciences Ireland Uc
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45094284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP19078196(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland Uc, Gilead Sciences Inc filed Critical Janssen Sciences Ireland Uc
Publication of ECSP19078196A publication Critical patent/ECSP19078196A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención presenta tabletas multicapas que contienen rilpivirina clorhidrato, emtricitabina y tenofivir disoproxil fumarato. Las tabletas son útiles para el tratamiento del HIV.
ECSENADI201978196A 2010-11-19 2019-10-30 Composiciones terapéuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato ECSP19078196A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41560010P 2010-11-19 2010-11-19

Publications (1)

Publication Number Publication Date
ECSP19078196A true ECSP19078196A (es) 2019-11-30

Family

ID=45094284

Family Applications (2)

Application Number Title Priority Date Filing Date
ECSP13012700 ECSP13012700A (es) 2010-11-19 2013-06-18 Composiciones terapéuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato
ECSENADI201978196A ECSP19078196A (es) 2010-11-19 2019-10-30 Composiciones terapéuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ECSP13012700 ECSP13012700A (es) 2010-11-19 2013-06-18 Composiciones terapéuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato

Country Status (35)

Country Link
US (1) US10857102B2 (es)
EP (2) EP2640362B2 (es)
JP (2) JP2014500261A (es)
KR (1) KR101923103B1 (es)
CN (2) CN106511357A (es)
AP (1) AP3816A (es)
AR (2) AR084500A1 (es)
AU (3) AU2011329642B2 (es)
BR (1) BR112013012245B1 (es)
CA (1) CA2818097C (es)
CL (1) CL2013001402A1 (es)
CO (1) CO6761300A2 (es)
CR (1) CR20130293A (es)
DK (1) DK2640362T4 (es)
EA (2) EA025852B1 (es)
EC (2) ECSP13012700A (es)
ES (1) ES2524408T5 (es)
HK (2) HK1190064A1 (es)
HR (1) HRP20140946T1 (es)
IL (1) IL226300B (es)
MA (1) MA34735B1 (es)
ME (1) ME01980B (es)
MX (1) MX347512B (es)
MY (1) MY185604A (es)
NZ (1) NZ610729A (es)
PE (3) PE20140163A1 (es)
PL (1) PL2640362T5 (es)
PT (1) PT2640362E (es)
RS (1) RS53691B1 (es)
SG (3) SG10201912527XA (es)
SM (1) SMT201400150B (es)
TW (1) TWI556840B (es)
UA (1) UA114075C2 (es)
WO (1) WO2012068535A1 (es)
ZA (1) ZA201304481B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040224917A1 (en) 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
KR101923103B1 (ko) 2010-11-19 2018-11-28 길리애드 사이언시즈, 인코포레이티드 릴피비린 hcl 및 테노포비어 디소프록실 푸마레이트를 포함하는 치료 조성물
AU2012296622C1 (en) 2011-08-16 2017-02-16 Gilead Sciences, Inc. Tenofovir alafenamide hemifumarate
CA2779052A1 (en) * 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
KR102527797B1 (ko) 2012-12-21 2023-05-03 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
EP2832351A1 (en) * 2013-07-29 2015-02-04 Sanovel Ilac Sanayi ve Ticaret A.S. Multilayer Tablet Formulations Comprising Tenofovir and Entecavir
CZ2013985A3 (cs) * 2013-12-09 2015-06-17 Zentiva, K.S. Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
WO2015152433A1 (en) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
ES2892123T3 (es) 2014-12-26 2022-02-02 Univ Emory Derivados antivíricos de N4-hidroxicitidina
US9839212B2 (en) 2015-04-16 2017-12-12 Bio-Lab, Inc. Multicomponent and multilayer compacted tablets
CA2921336A1 (en) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
KR20170003063A (ko) * 2015-06-30 2017-01-09 한미약품 주식회사 테노포비어 디소프록실 함유 경구용 고형제제 및 그 제조방법
TWI737647B (zh) 2015-11-09 2021-09-01 美商基利科學股份有限公司 用於治療人類免疫缺乏病毒之治療組合物
US20190060325A1 (en) * 2016-04-08 2019-02-28 Shionogi & Co., Ltd. Stabilized solid dosage form
TR201617448A2 (tr) * 2016-11-29 2018-06-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Tenofovi̇r ve emtri̇si̇tabi̇n i̇çeren kati oral farmasöti̇k bi̇leşi̇mler
US10561614B2 (en) * 2017-01-27 2020-02-18 Steerlife India Private Limited Tenofovir granules
WO2019003150A2 (en) * 2017-06-30 2019-01-03 Viiv Healthcare Company ASSOCIATION, USES AND THERAPEUTIC DIAGRAMS
GB2581936B (en) 2017-12-07 2021-02-10 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
JP2022538338A (ja) * 2019-07-03 2022-09-01 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー リルピビリンを用いて小児患者におけるｈｉｖを治療する方法
CN112137981A (zh) * 2020-11-02 2020-12-29 成都晶富医药科技有限公司 富马酸丙酚替诺福韦片及其制备工艺

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ250842A (en) 1991-02-22 1996-03-26 Univ Emory Resolution of a racemic mixture of nucleoside enantiomers such as 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (ftc)
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
EP1448170A4 (en) 2001-11-27 2010-05-12 Bristol Myers Squibb Co EFAVIRENZ STAMP PREPARATIONS HAVING UNIQUE BIOPHARMACEUTICAL CHARACTERISTICS
US20040224917A1 (en) 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
PL1632232T6 (pl) 2004-09-02 2022-06-27 Janssen Pharmaceutica Nv Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu
SI1632232T1 (sl) 2004-09-02 2011-09-30 Janssen Pharmaceutica Nv Sol 4((4((4-(2-cianoetenil)-2,6-dimetilfenil)amino)-2-pirimidinil)amino) benzonitrila
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
CA2625776A1 (en) 2005-10-14 2007-04-26 Microdose Technologies, Inc. Pharmaceutical packaging of an oral dosage combination
AU2006325404B2 (en) 2005-12-14 2012-03-01 Cipla Limited Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
ES2603617T3 (es) * 2007-02-23 2017-02-28 Gilead Sciences, Inc. Moduladores de propiedades farmacocinéticas de la terapéutica
WO2008140461A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
US20080286344A1 (en) 2007-05-16 2008-11-20 Olivia Darmuzey Solid form
EP2160394A1 (en) 2007-05-22 2010-03-10 Ultimorphix Technologies B.v. Tenofovir disoproxil hemi-fumaric acid co-crystal
WO2009037449A1 (en) 2007-09-18 2009-03-26 Cipla Limited Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors
WO2009106960A2 (en) 2008-02-27 2009-09-03 Aurobindo Pharma Limited Stable compositions of lamivudine, tenofovir and efavirenz
KR101784647B1 (ko) 2008-05-02 2017-10-11 길리애드 사이언시즈, 인코포레이티드 제약 제제의 가공성 향상을 위한 고체 담체 입자의 용도
AP3250A (en) 2009-02-06 2015-05-31 Gilead Sciences Inc Tablets for combination therapy
PE20160217A1 (es) 2009-09-21 2016-05-18 Gilead Sciences Inc Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales
WO2011077100A1 (en) 2009-12-24 2011-06-30 Cipla Limited Antiretroviral composition
KR101923103B1 (ko) 2010-11-19 2018-11-28 길리애드 사이언시즈, 인코포레이티드 릴피비린 hcl 및 테노포비어 디소프록실 푸마레이트를 포함하는 치료 조성물

Also Published As

Publication number Publication date
AP2013006931A0 (en) 2013-06-30
AU2018202635A1 (en) 2018-05-10
EP2826466A1 (en) 2015-01-21
EP2640362A1 (en) 2013-09-25
KR101923103B1 (ko) 2018-11-28
CA2818097A1 (en) 2012-05-24
HRP20140946T1 (hr) 2015-02-13
AU2011329642B2 (en) 2016-08-11
HK1190064A1 (en) 2014-06-27
AR084500A1 (es) 2013-05-22
MX347512B (es) 2017-04-28
JP2015131853A (ja) 2015-07-23
WO2012068535A1 (en) 2012-05-24
EA201390651A1 (ru) 2013-11-29
PT2640362E (pt) 2014-11-28
DK2640362T4 (da) 2022-03-07
MX2013005669A (es) 2013-11-04
CO6761300A2 (es) 2013-09-30
ECSP13012700A (es) 2013-08-30
CN106511357A (zh) 2017-03-22
ZA201304481B (en) 2022-03-30
KR20140037799A (ko) 2014-03-27
EP2640362B2 (en) 2021-12-01
HK1206592A1 (en) 2016-01-15
EP2640362B1 (en) 2014-09-10
AP3816A (en) 2016-09-30
EA025852B1 (ru) 2017-02-28
PE20170521A1 (es) 2017-05-27
CN103491948A (zh) 2014-01-01
SG10201509521WA (en) 2015-12-30
CL2013001402A1 (es) 2013-12-27
ES2524408T5 (es) 2022-04-25
PE20140163A1 (es) 2014-02-08
SMT201400150B (it) 2015-01-15
AU2011329642A1 (en) 2013-05-02
AR123409A2 (es) 2022-11-30
JP2014500261A (ja) 2014-01-09
TW201238612A (en) 2012-10-01
TWI556840B (zh) 2016-11-11
CA2818097C (en) 2019-07-30
IL226300B (en) 2019-05-30
US10857102B2 (en) 2020-12-08
BR112013012245B1 (pt) 2022-09-27
MA34735B1 (fr) 2013-12-03
PL2640362T3 (pl) 2015-03-31
UA114075C2 (xx) 2017-04-25
MY185604A (en) 2021-05-25
SG190333A1 (en) 2013-06-28
AU2016208417B2 (en) 2018-04-05
NZ610729A (en) 2015-10-30
AU2016208417A1 (en) 2016-08-18
CN103491948B (zh) 2016-11-02
RS53691B1 (en) 2015-04-30
EA201691695A1 (ru) 2017-11-30
ES2524408T3 (es) 2014-12-09
CR20130293A (es) 2013-10-03
JP6138851B2 (ja) 2017-05-31
ME01980B (me) 2015-05-20
US20130243857A1 (en) 2013-09-19
SG10201912527XA (en) 2020-02-27
BR112013012245A2 (pt) 2016-08-09
PL2640362T5 (pl) 2022-05-02
DK2640362T3 (en) 2014-12-01
PE20211657A1 (es) 2021-08-24

Similar Documents

Publication Publication Date Title
ECSP19078196A (es) Composiciones terapéuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
CR20150265A (es) Formas de dosificación de ruxolitinib de liberación sostenida
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
CR20150326A (es) Inhibidores de autotaxina
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
ECSP16078782A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
ECSP14013284A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
CY1121999T1 (el) Φαρμακοτεχνικες μορφες συνδυασμου δαρουναβιρης
MX2020003546A (es) Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento.
NZ738524A (en) Pharmaceutical formulations comprising rilpivirine hydrochloride, tenofovir alafenamide hemifumarate, and emtricitabine
CY1118074T1 (el) Ανθελονοσιακοι παραγοντες
CY1124041T1 (el) Συνθεσεις που περιλαμβανουν κυκλοσπορινη
UY31645A1 (es) Nuevas imidazolidinas fenil-sustituidas, procedimiento para su preparación, medicamentos que conprenden dichos compuestos y su uso.
CY1119785T1 (el) 2,4,6-τριφθορο-ν-[6-(1-μεθυλο-πιπεριδινο-4-καρβονυλο)-πυριδιν-2-υλο]-βενζαμιδιο για την αντιμετωπιση ημικρανιας μεσω της στοματικης ή της ενδοφλεβιας οδου
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?
DOP2016000161A (es) Ureas asimétricas p- sustituidas y usos médicos de las mismas.
BR112015024703A2 (pt) formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose
CY1118913T1 (el) Νεοι ανθελονοσιακοι παραγοντες
GT201500039A (es) Derivados de diazepinona útiles para el tratamiento del síndrome x frágil, enfermedad de parkinson o enfermedad de reflujo
CY1118255T1 (el) Υποκατεστημενα 6-αμινο-νικοτιναμιδια τα οποια φερουν μια ομαδα που περιεχει οη ως διαμορφωτες των kcnq2/3
TR201100151A2 (tr) İbandronate formülasyonu.